{"id":"fd17f1eefa1a","type":"article","url":"https://hartvaat.nl/2016/02/01/sprint-resultaten-en-implicaties-voor-de-nefrologie/","title":"SPRINT-resultaten en implicaties voor de nefrologie","title_en":"A SPRINT to the finish, or just the beginning? Implications of the SPRINT results for nephrologists.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","internist"],"tags":["atleten","ouderen","stride-trial"],"journal":"Kidney international","doi":"10.1016/j.kint.2015.12.024","source_url":"https://doi.org/10.1016/j.kint.2015.12.024","authors":["Michael V Rocco","Alfred K Cheung"],"significance":7,"published":"2016-02-01","source_date":"2016-02-01","image":"","kennis":["https://hartvaat.nl/kennis/hypertensie/hypertensie-en-ckd/","https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/"],"congress":"","summary_en":"This analysis assessed the implications of SPRINT results for nephrology practice, discussing how intensive blood pressure control affects kidney outcomes and the balance of cardiovascular benefit versus renal risk in CKD patients.","created":"2026-07-03T10:25:55Z","updated":"2026-07-03T13:25:17Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Analyse van de SPRINT-trial vanuit nefrologisch perspectief. Intensieve bloeddrukcontrole reduceerde cardiovasculaire events en mortaliteit significant, ook bij patiënten met chronische nierziekte. Bespreekt implicaties voor de nefrologische praktijk.","abstract_original":"The Systolic Blood Pressure Intervention Trial (SPRINT) demonstrated a significant reduction in major cardiovascular events and all-cause mortality with intensive blood pressure control in older individuals at high cardiovascular risk, including patients with chronic kidney disease and mild proteinuria. Nephrologists should consider the SPRINT results when determining the optimal blood pressure target for patients with chronic kidney disease."}